Approximately 90% of human cutaneous melanomas are driven in part by BRAF, RAS, NF1, and KIT mutations that confer constitutive mitogenic signaling through the MAPK pathway [24, 45, 54]. The gene discussed is NF1; the disease is cutaneous melanoma.